Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.

Advances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commerci...

Full description

Bibliographic Details
Main Authors: Dace Skrastina, Ivars Petrovskis, Ilva Lieknina, Janis Bogans, Regina Renhofa, Velta Ose, Andris Dishlers, Yuri Dekhtyar, Paul Pumpens
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4250084?pdf=render
id doaj-12bad5f3bcae4beab56ceb1d8bc16ffb
record_format Article
spelling doaj-12bad5f3bcae4beab56ceb1d8bc16ffb2020-11-24T22:00:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01912e11400610.1371/journal.pone.0114006Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.Dace SkrastinaIvars PetrovskisIlva LiekninaJanis BogansRegina RenhofaVelta OseAndris DishlersYuri DekhtyarPaul PumpensAdvances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commercially available Silica nanoparticles (initial particles size of 10-20 nm) with that of aluminium hydroxide, or Alum, as well as that of complete and incomplete Freund's adjuvants for the immunisation of BALB/c mice with virus-like particles (VLPs) formed by recombinant full-length Hepatitis B virus core (HBc) protein. The induction of B-cell and T-cell responses was studied after immunisation. Silica nanoparticles were able to adsorb maximally 40% of the added HBc, whereas the adsorption capacity of Alum exceeded 90% at the same VLPs/adjuvant ratio. Both Silica and Alum formed large complexes with HBc VLPs that sedimented rapidly after formulation, as detected by dynamic light scattering, spectrophotometry, and electron microscopy. Both Silica and Alum augmented the humoral response against HBc VLPs to the high anti-HBc level in the case of intraperitoneal immunisation, whereas in subcutaneous immunisation, the Silica-adjuvanted anti-HBc level even exceeded the level adjuvanted by Alum. The adjuvanting of HBc VLPs by Silica resulted in the same typical IgG2a/IgG1 ratios as in the case of the adjuvanting by Alum. The combination of Silica with monophosphoryl lipid A (MPL) led to the same enhancement of the HBc-specific T-cell induction as in the case of the Alum and MPL combination. These findings demonstrate that Silica is not a weaker putative adjuvant than Alum for induction of B-cell and T-cell responses against recombinant HBc VLPs. This finding may have an essential impact on the development of the set of Silica-adjuvanted vaccines based on a long list of HBc-derived virus-like particles as the biological component.http://europepmc.org/articles/PMC4250084?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Dace Skrastina
Ivars Petrovskis
Ilva Lieknina
Janis Bogans
Regina Renhofa
Velta Ose
Andris Dishlers
Yuri Dekhtyar
Paul Pumpens
spellingShingle Dace Skrastina
Ivars Petrovskis
Ilva Lieknina
Janis Bogans
Regina Renhofa
Velta Ose
Andris Dishlers
Yuri Dekhtyar
Paul Pumpens
Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
PLoS ONE
author_facet Dace Skrastina
Ivars Petrovskis
Ilva Lieknina
Janis Bogans
Regina Renhofa
Velta Ose
Andris Dishlers
Yuri Dekhtyar
Paul Pumpens
author_sort Dace Skrastina
title Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
title_short Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
title_full Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
title_fullStr Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
title_full_unstemmed Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
title_sort silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis b core virus-like particles.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Advances in nanotechnology and nanomaterials have facilitated the development of silicon dioxide, or Silica, particles as a promising immunological adjuvant for the generation of novel prophylactic and therapeutic vaccines. In the present study, we have compared the adjuvanting potential of commercially available Silica nanoparticles (initial particles size of 10-20 nm) with that of aluminium hydroxide, or Alum, as well as that of complete and incomplete Freund's adjuvants for the immunisation of BALB/c mice with virus-like particles (VLPs) formed by recombinant full-length Hepatitis B virus core (HBc) protein. The induction of B-cell and T-cell responses was studied after immunisation. Silica nanoparticles were able to adsorb maximally 40% of the added HBc, whereas the adsorption capacity of Alum exceeded 90% at the same VLPs/adjuvant ratio. Both Silica and Alum formed large complexes with HBc VLPs that sedimented rapidly after formulation, as detected by dynamic light scattering, spectrophotometry, and electron microscopy. Both Silica and Alum augmented the humoral response against HBc VLPs to the high anti-HBc level in the case of intraperitoneal immunisation, whereas in subcutaneous immunisation, the Silica-adjuvanted anti-HBc level even exceeded the level adjuvanted by Alum. The adjuvanting of HBc VLPs by Silica resulted in the same typical IgG2a/IgG1 ratios as in the case of the adjuvanting by Alum. The combination of Silica with monophosphoryl lipid A (MPL) led to the same enhancement of the HBc-specific T-cell induction as in the case of the Alum and MPL combination. These findings demonstrate that Silica is not a weaker putative adjuvant than Alum for induction of B-cell and T-cell responses against recombinant HBc VLPs. This finding may have an essential impact on the development of the set of Silica-adjuvanted vaccines based on a long list of HBc-derived virus-like particles as the biological component.
url http://europepmc.org/articles/PMC4250084?pdf=render
work_keys_str_mv AT daceskrastina silicananoparticlesastheadjuvantfortheimmunisationofmiceusinghepatitisbcoreviruslikeparticles
AT ivarspetrovskis silicananoparticlesastheadjuvantfortheimmunisationofmiceusinghepatitisbcoreviruslikeparticles
AT ilvalieknina silicananoparticlesastheadjuvantfortheimmunisationofmiceusinghepatitisbcoreviruslikeparticles
AT janisbogans silicananoparticlesastheadjuvantfortheimmunisationofmiceusinghepatitisbcoreviruslikeparticles
AT reginarenhofa silicananoparticlesastheadjuvantfortheimmunisationofmiceusinghepatitisbcoreviruslikeparticles
AT veltaose silicananoparticlesastheadjuvantfortheimmunisationofmiceusinghepatitisbcoreviruslikeparticles
AT andrisdishlers silicananoparticlesastheadjuvantfortheimmunisationofmiceusinghepatitisbcoreviruslikeparticles
AT yuridekhtyar silicananoparticlesastheadjuvantfortheimmunisationofmiceusinghepatitisbcoreviruslikeparticles
AT paulpumpens silicananoparticlesastheadjuvantfortheimmunisationofmiceusinghepatitisbcoreviruslikeparticles
_version_ 1725845217126383616